Bullish Case: DRUG’s return surface is thickest around small mean‑reverting moves, and the tape matches (≈+26% vs 1 month ago, still ≈-8% vs 60d). Call volume is 12% > put volume, and DRUG IV near ~80 strikes is far lower than extreme deep puts—downside tail feels priced but not “starting now.” If no dilution/clinical shock appears before 07/17–08/21 expiries, a +5% to +10% pop stays plausible; the earlier squeeze thesis lagged.

Bearish Case: Downside skew remains visible: DRUG deep OTM put IVs (e.g., 40P/45P) are hundreds+, while near‑ATM IV is comparatively tame—classic “crash-risk” pricing. DRUG has also slipped ~-8% over 60d, and Helium’s forecast has negative realized correlation (-0.4), so bullish AI signals can fade. SPY IV is not collapsing (risk-off spillover plausible). A falsifiable catalyst is an equity shelf/dilution or adverse trial/reg update before 07/17, targeting -10% to -25%.

Potential Outcomes:

1. 30%: -5%..+8% mean-revert by 07/17 if no SEC/PR catalyst; densest band on DRUG return surface is near small moves.
2. 20%: +10%..+20% on efficacy/partner headline before 08/21 (would compress put-skew implied by the IV surface).
3. 24%: -10%..-25% on shelf/dilution (validated by a filing/financing PR) in weeks.
4. 13%: -30%..-45% crash on adverse trial/reg decision (deep put IV stays extreme).
5. 13%: -5%..+5% churn with high skew; oracle framing: event-window call spread financed by put spread around 07/17/08/21.

July 11, 2026